SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) March 29, 1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today, that a
Diasensor 1000 Noninvasive Blood Glucose Monitor was
delivered to the Food and Drug Administration (FDA)
following the conclusion of a technical seminar
presented to FDA staff members at the Company's
Indiana, PA facilities on March 23 and 24, 1999. The
FDA purchased the Diasensor 1000, which is already
approved for sale in the 15-country European Union, in
order to evaluate its performance characteristics and
conduct laboratory and clinical research on noninvasive
monitoring.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: March 29, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL DELIVERS DIASENSOR 1000 TO THE FDA
Pittsburgh, PA - March 29, 1999 - Biocontrol Technology,
Inc. (OTCBB:BICO) announced today, that a Diasensor 1000
Noninvasive Blood Glucose Monitor was delivered to the Food and
Drug Administration (FDA) following the conclusion of a technical
seminar presented to FDA staff members at the Company's Indiana,
PA facilities on March 23 and 24, 1999.
The FDA purchased the Diasensor 1000, which is already
approved for sale in the 15-country European Union, in order to
evaluate its performance characteristics and conduct laboratory
and clinical research on noninvasive monitoring. The purpose of
the seminar was to educate the attending FDA staff members
regarding the application, operation, and maintenance of the
device. Biocontrol will continue to assist the FDA, as
requested, in their study of this new noninvasive technology.
David L. Purdy, president of Biocontrol, stated "The FDA
personnel who attended the seminar were very knowledgeable about
existing invasive glucose testing technology, and the Biocontrol
presentation was designed to extend FDA personnel's understanding
of the Company's noninvasive technology used in the Diasensor
1000. Both the FDA and Biocontrol personnel profited from the
interchange of concepts embodied in the Diasensor."
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. Biocontrol has
the exclusive rights to the research and development and
manufacturing of the Diasensor 1000. Subsidiary Diasensor.com,
Inc., also located in Pittsburgh, PA, owns the patent, marketing
and distribution rights to the sensor.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204